IS4979A - Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF) - Google Patents

Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)

Info

Publication number
IS4979A
IS4979A IS4979A IS4979A IS4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A
Authority
IS
Iceland
Prior art keywords
laxatives
pde
tnf
production
necrosis factor
Prior art date
Application number
IS4979A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of IS4979A publication Critical patent/IS4979A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS4979A 1996-09-04 1999-02-16 Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF) IS4979A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2544696P 1996-09-04 1996-09-04
PCT/IB1997/001023 WO1998009961A1 (en) 1996-09-04 1997-08-25 Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (1)

Publication Number Publication Date
IS4979A true IS4979A (is) 1999-02-16

Family

ID=21826124

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4979A IS4979A (is) 1996-09-04 1999-02-16 Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)

Country Status (35)

Country Link
US (1) US6262040B1 (is)
EP (1) EP0931075A1 (is)
JP (2) JP3554337B2 (is)
KR (1) KR100338610B1 (is)
CN (1) CN1234031A (is)
AP (1) AP795A (is)
AR (1) AR008162A1 (is)
AU (1) AU724549B2 (is)
BG (1) BG64447B1 (is)
BR (1) BR9712005A (is)
CA (1) CA2264798A1 (is)
CO (1) CO4600636A1 (is)
DZ (1) DZ2303A1 (is)
EA (1) EA002113B1 (is)
GT (1) GT199700102A (is)
HN (1) HN1997000126A (is)
HR (1) HRP970478B1 (is)
HU (1) HUP9903248A3 (is)
ID (1) ID18157A (is)
IL (1) IL128642A0 (is)
IS (1) IS4979A (is)
MA (1) MA26439A1 (is)
NO (1) NO991048L (is)
NZ (1) NZ334213A (is)
OA (1) OA10985A (is)
PA (1) PA8437301A1 (is)
PE (1) PE107998A1 (is)
PL (1) PL332187A1 (is)
SK (1) SK27299A3 (is)
TN (1) TNSN97148A1 (is)
TR (1) TR199900481T2 (is)
TW (1) TW402595B (is)
WO (1) WO1998009961A1 (is)
YU (1) YU11299A (is)
ZA (1) ZA977903B (is)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934307B1 (en) 1996-06-19 2011-04-27 Aventis Pharma Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
IL135714A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
YU25000A (sh) * 1997-11-04 2003-12-31 Pfizer Products Inc. Indazol bioizoster zamena katehola u terapeutski aktivnim jedinjenjima
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
US6191300B1 (en) 1999-04-16 2001-02-20 Eastman Chemical Company Process for the preparation of cyclopropylacetonitrile
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CA2447619A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for accelerating bone fracture healing
ES2427930T3 (es) * 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20050118715A1 (en) * 2002-04-12 2005-06-02 Hariri Robert J. Modulation of stem and progenitor cell differentiation, assays, and uses thereof
KR20050008757A (ko) * 2002-05-30 2005-01-21 셀진 코포레이션 세포 분화를 조절하고 골수증식성 질환 및 골수형성이상증후군을 치료하기 위하여 ｊｎｋ 또는 ｍｋｋ 저해제를사용하는 방법
WO2004009552A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
ES2323688T3 (es) * 2002-07-19 2009-07-23 Memory Pharmaceuticals Corporation Compuestos de 4-aminobenzofurano como inhibidores de fosfodiesterasa 4.
NZ540138A (en) 2002-11-19 2008-07-31 Memory Pharm Corp Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL379330A1 (pl) 2002-12-20 2006-08-21 Pfizer Products Inc. Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
JP2005089457A (ja) * 2003-09-03 2005-04-07 Yung Shin Pharmaceutical Industry Co Ltd 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP1737865A1 (en) 2004-02-27 2007-01-03 F.Hoffmann-La Roche Ag Fused derivatives of pyrazole
CA2558109A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Heteroaryl-fused pyrazolo derivatives
KR20060114022A (ko) 2004-02-27 2006-11-03 에프. 호프만-라 로슈 아게 인다졸 유도체 및 그들을 함유하는 약학 조성물
CA2566477A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111016A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
CN1997626A (zh) * 2004-07-12 2007-07-11 默克公司 组蛋白脱乙酰基酶的抑制剂
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
TW200621237A (en) 2004-11-01 2006-07-01 Wyeth Corp [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
MX2008002588A (es) 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de p38-map-cinasa y los metodos para utilizarlos.
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US8044083B2 (en) 2006-01-31 2011-10-25 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
WO2008026687A1 (fr) 2006-09-01 2008-03-06 Kyorin Pharmaceutical Co., Ltd. Dérivé de pyrazolopyridine carboxamide et inhibiteur de phosphodiestérase (pde) comprenant le dérivé
AU2007329480A1 (en) * 2006-12-05 2008-06-12 National Chio Tung University Indazole compounds
CN101801376A (zh) 2007-03-14 2010-08-11 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
CA2755768A1 (en) * 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CN102939283B (zh) * 2010-04-22 2015-06-03 詹森药业有限公司 可用作己酮糖激酶抑制剂的吲唑化合物
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
AU2017360939B2 (en) * 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
KR20220045954A (ko) 2019-07-11 2022-04-13 이스케이프 바이오, 인크. Lrrk2 억제제들로서의 인다졸들 및 아자인다졸들
CN112694474B (zh) * 2019-10-23 2022-03-18 四川大学 吲唑类衍生物及其制备方法和用途
EP4347110A1 (en) * 2021-05-31 2024-04-10 Genscript USA Inc. Electrografted films for dna synthesis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531433A (is) * 1953-06-17
US4665397A (en) 1983-11-01 1987-05-12 Universal Photonics, Inc. Apparatus and method for a universal electronic locking system
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPH061350B2 (ja) * 1985-07-26 1994-01-05 コニカ株式会社 ハロゲン化銀写真感光材料
JPS6250751A (ja) * 1985-08-29 1987-03-05 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
GB8609175D0 (en) * 1986-04-15 1986-05-21 Ici America Inc Heterocyclic carboxamides
ES2095855T3 (es) * 1989-02-02 1997-03-01 Yamanouchi Pharma Co Ltd Derivados de tetrahidrobencimidazol.
DE59010701D1 (de) * 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
CN1048015C (zh) * 1993-07-06 2000-01-05 美国辉瑞有限公司 双环四氢吡唑并吡啶类化合物
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
EP0745063B1 (en) 1994-02-17 1999-03-24 American Home Products Corporation Substituted biphenyl derivatives as phosphodiesterase inhibitors
WO1995027692A1 (en) * 1994-04-08 1995-10-19 Smithkline Beecham Corporation Subtituted biphenyl tnf inhibitors
JPH08143525A (ja) * 1994-11-21 1996-06-04 Banyu Pharmaceut Co Ltd ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤
CN1080260C (zh) * 1996-06-25 2002-03-06 美国辉瑞有限公司 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途
ES2168581T3 (es) * 1996-06-27 2002-06-16 Pfizer Derivados de indazol sustituidos.

Also Published As

Publication number Publication date
NO991048D0 (no) 1999-03-03
WO1998009961A1 (en) 1998-03-12
YU11299A (sh) 2001-07-10
DZ2303A1 (fr) 2002-12-28
PA8437301A1 (es) 1999-12-27
HN1997000126A (es) 1997-12-26
AP9701080A0 (en) 1997-10-31
MA26439A1 (fr) 2004-12-20
NZ334213A (en) 2000-08-25
PL332187A1 (en) 1999-08-30
TNSN97148A1 (fr) 2005-03-15
HUP9903248A2 (hu) 2000-04-28
SK27299A3 (en) 2000-10-09
PE107998A1 (es) 1999-01-30
ZA977903B (en) 1999-03-03
CA2264798A1 (en) 1998-03-12
JP3554337B2 (ja) 2004-08-18
AP795A (en) 1999-12-28
GT199700102A (es) 1999-02-25
TR199900481T2 (xx) 1999-06-21
AU3781397A (en) 1998-03-26
AR008162A1 (es) 1999-12-09
IL128642A0 (en) 2000-01-31
CO4600636A1 (es) 1998-05-08
ID18157A (id) 1998-03-05
CN1234031A (zh) 1999-11-03
AU724549B2 (en) 2000-09-28
EA199900183A1 (ru) 1999-08-26
KR20000068421A (ko) 2000-11-25
BG64447B1 (en) 2005-02-28
BG103195A (en) 1999-09-30
TW402595B (en) 2000-08-21
HRP970478A2 (en) 1998-08-31
KR100338610B1 (ko) 2002-05-27
HUP9903248A3 (en) 2000-07-28
JP2000502724A (ja) 2000-03-07
HRP970478B1 (en) 2002-10-31
BR9712005A (pt) 1999-08-24
EP0931075A1 (en) 1999-07-28
US6262040B1 (en) 2001-07-17
NO991048L (no) 1999-05-03
OA10985A (en) 2001-11-01
EA002113B1 (ru) 2001-12-24
JP2004217668A (ja) 2004-08-05

Similar Documents

Publication Publication Date Title
IS4979A (is) Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)
IS4871A (is) Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF)
IS4910A (is) Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata
AU2001296609A1 (en) High-density metal capacitor using dual-damascene copper interconnect
EP0987263A3 (en) Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
DE69633503D1 (de) 1,2,4- triazolo (4,3-b) pyridazinderivate und ihre verwendung
PL365824A1 (en) Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
IS5654A (is) Aðferð til framleiðslu á pýrazóló[4,3-d]pýrimidín-7-ón-3-pýridýlsúlfónýl efnasamböndum og milliefnum af þeim
NO934227D0 (no) Pyrrolderivater, fremgangsm}te for deres fremstilling og terapeutiske anvendelse
AU5022400A (en) Tumor necrosis factor receptor 5
DE69707293D1 (de) Pyrrolo(3,2-c)chinolin-derivate
AU2002249706A1 (en) Plate and tube join and method